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Autogenous saphenous vein is the graft material
of choice for patients who need lower extremity
bypass operations. For patients who lack adequate
autogenous saphenous vein, alternative graft materi-
als must be considered. Venous allografts would
appear to be an attractive substitute for autogenous
saphenous vein, because they provide an endotheli-
um-lined human biologic conduit. Although it has
been claimed that allografts of blood vessels might
be successful because of minimal immunogenicity,1
these grafts are subject to frequent and early failure,
the cause of which has not been thoroughly investi-
gated. Transplant rejection plays a role in the failure
of venous allografts,2 but the details of this process
have not yet been studied.
METHODS
Trial design. In the context of a prospective,
randomized trial approved by the human subjects
committee of the University of Pennsylvania, 40
patients with rest pain or tissue loss or both who
needed bypass to pedal or crural outflow and who
lacked adequate available autogenous saphenous
vein underwent bypass with cryopreserved saphe-
nous venous allograft. Patients were randomized to
receive (17 patients) or not receive (23 patients) aza-
thioprine (1 mg/kg per day) after bypass. Details of
trial design and the description of clinical outcomes
for these 40 patients are in a previous report.3
Venous allografts. Cryopreserved saphenous
venous allografts were obtained from Cryolife
Cardiovascular, Marietta, Ga. Veins were stored in a
dimethyl sulfoxide–containing solution at –196° C.
Single-donor veins only (no composite allografts)
were used. All grafts were larger than 4 mm in diam-
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eter and were ABO blood group matched to the
recipient. All patients underwent biopsies of the
allografts at the time of implantation. Twenty-two
patients underwent biopsies of previously implanted
allografts at the time of subsequent graft revision or
amputation. Biopsies of thrombosed grafts (n = 20)
were taken from patent portions of the graft (anas-
tomotic region).
Histologic and immunohistochemical analysis.
Standard hematoxylin and eosin preparations were
made of implanted and explanted allografts. Paraffin
immunohistochemical study was performed with
standard avidin-biotin complex technique, capillary
gap technology, and a robotic immunostainer
(Ventanna-Biotek, Tuscon, Ariz.). Hematoxylin and
eosin and immunostained slides were evaluated in a
semiquantitative manner by one pathologist (J.E.T.).
Scoring was performed according to the following
scale: 0, no label and no change; 1+, less than 2% of
compartment labeled or affected by feature; 2+, 3% to
10% of compartment labeled or affected by feature;
3+, moderate, 11% to 50% of compartment labeled or
affected by feature; 4+, heavy or severe, more than
50% of compartment labeled or affected by feature.
Monoclonal antibodies used and their activity are list-
ed in Table I. Antibodies were obtained from DAKO
(Carpenteria, Calif.), except for CD56 (Monosan,
Amudon, The Netherlands) and TIA-1 (Coulter,
Hialeah, Fla.). Each explanted graft was tested with all
antibodies.
Statistical analysis. Analysis of variance and
correlation between antibody markers, histologic
findings, and graft and patient characteristics were
performed with Statview statistical software (Abacus
Concepts, Berkeley, Calif.). A c 2 or Fisher’s exact
test was performed for categorical variables and cor-
relation coefficient with r to z conversion for con-
tinuous variables. All tests were two-sided. Signi-
ficance was defined as a p value less than 0.05. All
grafts were included in each analysis.
RESULTS
Clinical trial. Full clinical results are reported
elsewhere3 but are summarized briefly herein. Forty
patients underwent allograft bypass grafting. During
the 31-month follow-up period (mean 15.7
months) the primary graft patency rate at 12 months
was 13%, and the limb salvage rate was 42%. No sig-
nificant difference (p < 0.05) was found between
immunosuppressed and control groups for graft
patency rate or limb salvage rate. Seven patients who
had negative results of preoperative anti-HLA anti-
body screens had conversion after surgical treat-
ment, and six patients had positive results of preop-
erative screens that became more strongly positive.3
Complications included one graft that underwent
aneurysmal degeneration that necessitated graft
removal
Pathologic specimens. All patients underwent
biopsies of allografts at the time of implantation.
Twenty-two patients underwent explantation of
allografts at the time of amputation or graft revision
and were the subject of this investigation. Nineteen
graft biopsies were adequate for histologic and
immunohistochemical investigation. The demo-
graphics of these patients are presented in Table II.
Use of immunosuppression. Patients who
received low-dose immunosuppression with azathio-
prine, when compared with controls did not demon-
strate a significant difference in histologic appear-
Table I. Monoclonal antibody assays
Antibody Target Clone/Reagent
CR3 HLA-DR CR3/43
CD31 Endothelium JC/70A
Factor VIII Endothelium A0082
SMA Smooth muscle actin 1A4
LCA Leukocytes 2Bll+PD7/26/16
CD3 T cells A0452
CD8 T cells, cytotoxic C8/144B
CD30 B cells Ber-H2
CD79 B cells JCBl17
L-26 B cells L26
CD35 Dendritic cells Ber-Mac-DTY
CD56 NK cells 123C3
TIA- 1 Cytotoxic granules 6604593
(NK and cytotoxic 
T cells)
Table II. Patient demographics (n = 19)
Demographic characteristic n (%)
Sex 8 male
11 female
Mean age (yr) 61 (range 43-82)
Race 9 white
10 black
Diabetes 16 (84)
Hypertension 15 (79)
Smoking 14 (74)
Coronary artery disease 10 (53)
Stroke 3 (16)
Creatinine >1.5 mg/dl 7 (37)
Prior vascular operation 19 (100)
Mean ankle-brachial index 0.11 (range 0.00-0.58)
Immunosuppression 6 (32)
Indication
Rest pain 6 (32)
Tissue loss 13 (68)
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ance. The presence of cytotoxic granules (TIA-1)
was significantly and negatively related (p < 0.05) to
immunosuppression. No other immunohistochemi-
cal markers demonstrated significant relations to
azathioprine administration.
Histologic and immunohistochemical find-
ings. Significant (p < 0.05) correlations among his-
tologic, clinical, and immunohistochemical variables
are summarized in Table III. All biopsy specimens
obtained at implantation were reviewed and were
found to be free of cellular infiltrates, medial necro-
sis, mural hemorrhage, capillary ingrowth, or intimal
thickening. Biopsy specimens uniformly reflected
some degree of preservation injury with characteris-
tic apoptosis in the outer layers of the venous allo-
graft.3 The inner layers of the allograft and the
endothelium appeared intact on all specimens.
Moderate or severe intimal thickening (Fig. 1)
was identified in nine patients (47%). No patients
had intimal thickening on implantation biopsies.
Quantity of intimal thickening was positively related
(p < 0.05) to quantity of mural hemorrhage and
medial necrosis and negatively correlated with quan-
tity of cytotoxic granules (TIA-1) and factor VIII.
There was a trend (p = 0.09) toward development of
intimal thickening with time after implantation.
Medial necrosis (Fig. 2) was identified in five
patients (26%). Quantity of medial necrosis correlat-
ed significantly (p < 0.05) with quantity of intimal
thickening and cytotoxic granules (TIA-1). Mural
hemorrhage (Fig. 2) was present in six patients
(32%). Hemorrhage was located in the vessel media
in three patients, the adventitia in three patients, and
in both the media and adventitia in one patient.
Quantity of mural hemorrhage was correlated (p <
0.05) with quantity of intimal thickening and cyto-
toxic granules (TIA-1).
Capillary ingrowth into the allograft wall (Fig. 3)
was appreciated in all but two patients (89%) and
was moderate or severe in five patients (26%).
Quantity of capillary ingrowth was significantly asso-
ciated (p < 0.05) with presence of a moderate or
severe cellular infiltrate and quantity of immunohis-
tochemical markers for leukocytes (LCA), T cells
(CD3 and CD8), HLA II-DR (CR3), and endothe-
lium (CD31 and factor VIII).
A cellular infiltrate was detected in all explanted
grafts with varying degrees of severity. Moderate or
severe infiltrates were present in six patients (32%).
Infiltrates were evenly distributed throughout the
intima, media, and adventitia. The infiltrates
appeared to be small, round lymphoid-appearing
cells on hematoxylin and eosin preparation (Fig. 4).
Presence of a moderate or severe cellular infiltrate
was significantly related (p < 0.05) to the presence of
moderate or severe capillary ingrowth and to the
quantity of immunohistochemical markers for
leukocytes (LCA), T cells (CD3 and CD8), and
HLA II-DR (CR3).
Leukocyte antigen (LCA) was detected in 16
patients (84%). The presence of LCA correlated sig-
nificantly (p < 0.05) with quantity of cellular infil-
Table III. Significant correlations (p < 0.05) between markers for 22 explanted allografts*
Variable Positive Correlation Negative Correlation
Graft patency duration — Factor VIII, CD31
Azathioprine immunosuppression — TIA-1
Cellular infiltrate Capillary ingrowth, LCA, CD3, CD8, CR3 —
Mural hemorrhage Intimal thickening, TIA-1 —
Medial necrosis Intimal thickening, TIA-1 —
Capillary ingrowth Cellular infiltrate, LCA, CD3, CD8, CR3, CD31, factor VIII —
Intimal thickening Mural hemorrhage, mural necrosis TIA-1, factor VIII
LCA Cellular infiltrate, capillary ingrowth, CD3, CR3, CD31, —
factor VIII
CD3 Cellular infiltrate, capillary ingrowth, LCA, CR3 SMA
CD8 Cellular infiltrate, capillary ingrowth, TIA-1, factor VIII —
CR3 Capillary ingrowth, LCA, CD3, CD31, factor VIII —
TIA-1 Mural hemorrhage, mural necrosis, CD8 Intimal thickening, 
azathioprine immuno-
suppression
SMA — CD3
CD31 Cellular infiltrate, capillary ingrowth, CD56, factor VIII, Graft patency duration
LCA, CD3
Factor VIII Capillary ingrowth, LCA, CD8, CR3, CD31 Intimal thickening, graft 
patency duration
*No significant correlations were identified for CD30, CD79, L-26, CD35, or CD56.
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trate, development of moderate or heavy capillary
ingrowth, and quantity of T cells (CD3), HLA II-
DR (CR3), and endothelium (CD31 and factor
VIII). The presence of HLA II-DR antigens, detect-
ed with CR3 staining, was associated significantly (p
< 0.05) with quantity of T cells (CD3), endothelium
(CD31 and factor VIII), and development of mod-
erate or heavy capillary ingrowth.
Quantity of cytotoxic granules (TIA-1; Fig. 5)
correlated significantly (p < 0.05) with quantity of
CD8-positive T cells and with quantity of mural
hemorrhage and medial necrosis. Patients who
were taking azathioprine showed significantly (p <
0.05) less TIA-1 than those not receiving immuno-
suppression. Presence of TIA-1 also correlated
negatively (p < 0.05) with quantity of intimal thick-
ening.
Presence of T-cell markers (CD3 and CD8; Figs.
6 and 7) was associated significantly (p < 0.05) with
presence of moderate or severe cellular infiltrates
and capillary ingrowth. Presence of CD8 was associ-
ated (p < 0.05) with quantity of cytotoxic granules
(TIA-1) and factor VIII. Quantity of CD3 correlat-
ed significantly (p < 0.05) with presence of LCA and
CR3 and correlated negatively (p < 0.05) with quan-
tity of smooth muscle actin (SMA).
Factor VIII expression occurred in all grafts and
expression of CD31 in 15 (79%). Presence of any of
these endothelial markers correlated (p < 0.05) with
presence of the others and with development of
moderate or heavy capillary ingrowth. It was nega-
tively related (p < 0.05) to duration of graft patency.
Fig. 2. Medial hemorrhage and necrosis. Necrotic media
shows loss of nuclear staining and dissecting acute hemor-
rhage (original magnification, 100 · ; hematoxylin and
eosin).
Fig. 3. Capillary ingrowth. Dense capillary network infil-
trating vessel wall in allograft with cellular rejection (orig-
inal magnification, 100· ; factor VIII immunostain).
Fig. 4. Dense cellular infiltrate of vessel wall in acute
rejection composed of many mononuclear cells with a
smaller number of neutrophils (original magnification,
200 · ; hematoxylin and eosin). 
Fig. 1. Fibrointimal hyperplasia. Intimal thickening par-
tially occludes graft lumen (original magnification, 100· ;
hematoxylin and eosin).
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Presence of CD31 also correlated positively (p <
0.05) with development of a moderate to severe cel-
lular infiltrate, presence of LCA, and quantity of T
cells (CD3). Factor VIII expression also was signifi-
cantly related (p < 0.05) to quantity of CD8 and
CR3 and negatively related (p < 0.05) to develop-
ment of moderate or severe intimal thickening.
Only trace numbers of B-cell markers (CD35,
CD30, L26, CD79) were detected and in few
patients (CD30, no patients; CD30, 1 patient; L26,
3 patients; CD79, 3 patients). No correlations were
identified between these or other markers or clinical
factors. The macrophage marker (CD68) was pre-
sent in five patients (26%) and had no significant
correlations.
DISCUSSION
Experimentation with venous allografts as an
arterial substitute has been pursued since Alexis
Carrell’s original description. Carrell implanted a
canine jugular venous allograft into the aorta of a
dog, and the graft remained patent for 2 years.4 We
have summarized elsewhere current clinical experi-
ence with venous allografts and our own results of
this prospective, randomized trial.3 Overall clinical
experience with venous allografts as substitutes for
small arteries (crural and pedal) has been disap-
pointing; 1-year patency rates range from 10% to
68%.5-14
We demonstrated a strong cell-mediated immune
response to allograft bypass in human subjects. Similar
and analogous findings of cellular infiltrates and dam-
age to the endothelium of solid organ transplants
have been described.2 Although no cellular infiltrates
were found at implantation biopsy, infiltrates of lym-
phoid cells developed in all patients. This is not mere-
ly a response to the cryopreservation process, as has
been demonstrated in canine experiments in which
dogs received cryopreserved autografts and did not
demonstrate an inflammatory response in explanted
specimens.15
Although it was originally hoped that cryo-
preservation might render allografts weakly anti-
genic or nonantigenic, this would appear not to be
the case. The inflammatory cells proved to be almost
entirely T cells, expressing CD3, CD8, and HLA-
DR antigens, signifying activation. Although
endothelial cells can act as antigen-presenting
cells,16-18 few other antigen-presenting cells were
seen, and most of the infiltrating population was
Fig. 5. Positive lymphoid cells with block and granular
staining for TIA-1 in cytotoxic granules (original magnifi-
cation, 200· ; immunoperoxidase stain).
Fig. 6. Positive lymphoid cells with strong staining for
the T-cell marker CD3 (original magnification, 200 · ;
immunoperoxidase stain).
Fig. 7. Positive lymphoid cells with strong staining for
the cytotoxic T-cell marker CD8 (original magnification,
200 · ; immunoperoxidase stain). 
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cytotoxic T cells (CD8). This implies the possibility
of an immune mechanism mediated by class I major
histocompatibility complex molecules that interact
directly with a T8 cell population (class I restricted)
rather than through class II antigens and antigen-
presenting cells. Recognition of venous allograft for-
eign major histocompatibility complex antigens
leads to activation of cytotoxic T cells (CD8, HLA-
DR). T cells also may have been stimulated to devel-
op cytolytic activity by the presence of anti-HLA
antibodies. Quantity of cytotoxic granules, associat-
ed with cytotoxic T cells and with antibody-depen-
dent cell-mediated cytotoxicity (ADCC) correlated
significantly with development of the cellular infil-
trate. Presence of this infiltrate and these cells corre-
lated with vessel wall destruction manifested as
mural hemorrhage and necrosis. With time, intimal
thickening occurred in response to injury, and capil-
lary ingrowth progressed, furthering the efficiency
of delivery of mediators of the immune response and
injury to the grafts.
As an alternative or in addition to this class I
restricted response, endothelial cells acting as anti-
gen-presenting cells may provide a class II mediated
response. It has been proposed that endothelium
may selectively stimulate transmigration of T cells
into the underlying parenchyma.19 We found that
quantity of endothelial markers (CD31, factor VIII)
was related to quantity of markers of the rejection
response (cellular infiltrate, capillary ingrowth,
CD3, LCA, CD8, CR3). An adverse correlation was
found between quantity of endothelial marker and
duration of patency of the grafts, which may offer
additional evidence of the role of the endothelium in
facilitating rejection.
In our previous report3 we described develop-
ment of anti-HLA antibodies in these patients.
Although we did not perform specific HLA typing
in this study, the development of these new anti-
HLA antibodies after bypass allografting suggests
that a humoral immune response may be engen-
dered by the allografts in addition to the cellular
response described herein. The development of anti-
HLA antibodies may contribute to graft failure in
several ways. Antibodies could opsonize the antigen-
bearing venous allograft, leading to activation of the
complement cascade. Antibodies also have been
associated with a cellular response (ADCC) mediat-
ed by cytotoxic granules. Although we detected few
macrophages and natural killer (NK) cells, ADCC
would be effected by binding of antibody to the
venous allograft with resultant binding of NK cells
and macrophages to the Fc portion by means of
their Fc receptors. This endows these cells with anti-
gen specificity for the allograft by means of specific
antibodies.
Endothelial markers declined in association with
time and the rejection response. It is possible that
the endothelium, known to be the locus of strongest
antigenicity in cellular rejection, was destroyed pro-
gressively in the process. Factor VIII expression and
CD31 quantity declined with duration of graft
patency. The decrease in endothelial markers was
proportional to the increase in activated, cytotoxic
T-cell infiltrate. Intimal thickening, a marker of
injury, also correlated with loss of endothelium.
Because rejection plays a role in failure of venous
allografts, it is natural to suggest that antirejection
therapy might augment venous allograft survival.
Azathioprine is a purine analogue the immunosup-
pressive effect of which is related to the ability of the
drug to interfere with lymphocyte mitosis. Use of
this agent constitutes relatively safe but weak
immunosuppression. Earlier canine experiments in
which azathioprine was used showed mixed results
with respect to prolongation of venous allograft
patency.20-22 We chose to use low-dose azathioprine
with the hope that a clinically significant effect could
be demonstrated with minimal patient risk. The
quantity of cytotoxic granules was significantly
smaller in explanted grafts from patients who
received azathioprine than in controls; the other
markers of rejection, however, were unaffected, and
the clinical effect of azathioprine on patency was
insignificant.3
Experiments with dogs and miniature swine have
shown that the use of cyclosporine prolongs venous
allograft survival.23-30 Cyclosporine is a potent
inhibitor of T-cell activation. Administration of
cyclosporine to human subjects has been associated
with hepatic and renal toxicity as well as infectious
and neoplastic complications of immunosuppres-
sion.31 It has been reported that human renal trans-
plant recipients receiving immunosuppressive therapy
with cyclosporine, azathioprine, and prednisone who
also received cryopreserved arterial allografts demon-
strated absence of rejection in two explanted failed
allografts. This finding indicates that use of potent
immunosuppression may alter the rejection response
in human subjects.32 A preliminary study of potent
immunosuppression for human recipients of venous
allografts demonstrated admirable patency with high-
dose immunosuppression,33 although a controlled
clinical trial is necessary to clearly establish the effect.
It is likely that with the use of more potent immuno-
suppressive agents, the rejection response, both
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humoral and cellular, can be decreased and allograft
patency augmented. The cost of this in terms of
immunosuppressive morbidity is unknown.
HLA matching of donors and recipients in one
study had a significant effect on patency of venous
allografts in miniature swine.34 Given the limited
numbers of venous allografts available, HLA match-
ing is not feasible for clinical applications, and only
ABO compatibility was evaluated in that study. The
importance of ABO and HLA matching for humans
has not been well studied.
Some allografts fail with only limited evidence of
rejection as a contributing cause. It is presumed that
these grafts failed for reasons related to local injury,
stasis, or other common causes of failure of venous
grafts. Many of these causes of graft failure involve
local hypercoagulability. Our patients received
aspirin, because it has been demonstrated that
antiplatelet drugs improve venous allograft patency
in animal experiments.28,35 Experience with pros-
thetic grafts has demonstrated increased patency
with the use of warfarin anticoagulation.36 It is pos-
sible that adjunctive use of warfarin may further aug-
ment venous allograft patency. 
We conclude that rejection contributes to failure
of human cryopreserved venous allografts. The
process involves cell-mediated immunity to venous
allografts and is not eliminated with low-dose aza-
thioprine. There is also indirect evidence of partici-
pation of humoral immunity in venous allograft
rejection. Rejection as a cause of venous allograft
failure may be diminished by use of more potent
immunosuppression and better matching of donors
and recipients. Improvement in procurement and
preservation techniques and adjunctive use of anti-
coagulation may augment venous allograft patency.
The authors wish to thank Clyde F. Barker, MD, and
Ali Naji, MD, PhD, for advice and support throughout
this study.
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